EU Medicines Agency @EMA_News@respublicae.eu

The agenda of EMA's human
https://nitter.cz/search?q=%23medicines
committee
https://nitter.cz/search?q=%23CHMP
is now published. 💊💉
Find out what medicines will be discussed this month:
https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-22-25-january-2024_en.pdf
The committee highlights will be released on Friday.

🐦🔗: https://nitter.cz/EMA_News/status/1749422543142822083#m

[2024-01-22 13:23 UTC]

RT by @EMA_News: Join us for a Conversation on Cancer Feb. 1 for World Cancer Day with @EMA_News. The panel of patients, investigators & regulators will discuss new therapies revolutionizing care for patients with chronic myeloid leukemia, multiple myeloma & melanoma. https://www.surveymonkey.com/r/HDNCD2Y

🐦🔗: https://nitter.cz/FDAOncology/status/1747967134162887005#m

[2024-01-18 13:00 UTC]

‼️ EMA will hold its first press briefing of 2024, where we will be discussing key developments in human
https://nitter.cz/search?q=%23medicines
throughout 2023.
It will be broadcast live 🔴 today, 16 Jan, from 14:30 to 15:00 CET.
https://nitter.cz/search?q=%23EMAPresser
👉
https://www.ema.europa.eu/en/events/ema-press-briefing-human-medicines-highlights-2023

🐦🔗: https://nitter.cz/EMA_News/status/1747243954062451128#m

[2024-01-16 13:06 UTC]

R to @EMA_News: We will start the press briefing at 14h30 CET

🐦🔗: https://nitter.cz/EMA_News/status/1747247687441731771#m

[2024-01-16 13:21 UTC]

R to @EMA_News: Watch live 🔴

We are now starting our press briefing on medicines that were approved last year and trends we are observing in human medicines.

Don’t miss our tweets 🧵 during the press briefing. Follow #EMAPresser

🐦🔗: https://nitter.cz/EMA_News/status/1747250220000289243#m

[2024-01-16 13:31 UTC]

R to @EMA_News: We published an overview of human medicines highlights this morning ⬇️

#EMAPresser

https://x.com/EMA_News/status/1747204037701669370?s=20

🐦🔗: https://nitter.cz/EMA_News/status/1747250732598751700#m

[2024-01-16 13:33 UTC]

R to @EMA_News: Therapeutic areas with the highest numbers of new approval recommendations:
1⃣ oncology,
2⃣ neurology,
3⃣ cardiovascular.

#EMAPresser

🐦🔗: https://nitter.cz/EMA_News/status/1747251070345077176#m

[2024-01-16 13:34 UTC]

R to @EMA_News: Outstanding medicines:
🔶1st product using new gene-editing technology #CRISPR/Cas9 to treat rare blood disorders
🔶2 vaccines against #RSV
🔶new medicines for children, one to treat heart failure and the other to prevent hearing loss or balance problems in chemotherapy patients.

🐦🔗: https://nitter.cz/EMA_News/status/1747251714670158120#m

[2024-01-16 13:37 UTC]

R to @EMA_News: Half of our positive recommendations on new therapeutic indications for existing medicines were for treatment of children 👦👧

This figure is considerably higher than in previous years.

#EMAPresser #MedicinesForChildren

🐦🔗: https://nitter.cz/EMA_News/status/1747252124348723345#m

[2024-01-16 13:39 UTC]

R to @EMA_News: We provided 2 recommendations for use of medicines outside the 🇪🇺 (#EUM4All):
🔶 a new treatment option for 50 million children with a tropical disease caused by parasites
🔶a medicine to treat an acute and lethal form of sleeping sickness

@WHO #EMAPresser #GlobalHealth

🐦🔗: https://nitter.cz/EMA_News/status/1747252409414602791#m

[2024-01-16 13:40 UTC]

R to @EMA_News: In 2023, we approved 8 #biosimilars for a wide range of diseases, including a rare genetic disease, #cancers, #multiplesclerosis.

The total of 9⃣7⃣ biosimilars that can be marketed in 🇪🇺 make treatments more accessible and can improve the quality of life for more #patients.

🐦🔗: https://nitter.cz/EMA_News/status/1747252697924006358#m

[2024-01-16 13:41 UTC]

R to @EMA_News: Last year, we also continued our work to tackle #COVID19, in particular with the evaluation of a new vaccine and 3 updated vaccines. 💉

#EMAPresser #COVID19Vaccines

🐦🔗: https://nitter.cz/EMA_News/status/1747253014438838691#m

[2024-01-16 13:42 UTC]

R to @EMA_News: We are committed to progressing treatments against #cancer and to supporting Europe’s beating cancer plan.

Cancer is an area of high unmet medical need and a major health concern in the 🇪🇺.

#EMAPresser #EUCancerPlan #HealthUnion

🐦🔗: https://nitter.cz/EMA_News/status/1747253264356405351#m

[2024-01-16 13:43 UTC]

R to @EMA_News: A third of all new medicines with a positive opinion in 2023 targeted cancer , i.e. 2⃣5⃣ new cancer medicines were recommended for approval last year.

#EMAPresser

🐦🔗: https://nitter.cz/EMA_News/status/1747253496460784019#m

[2024-01-16 13:44 UTC]

R to @EMA_News: To support development and earlier assessment of medicines that address unmet medical needs for #cancer patients
➡️ 7 were reviewed in view of a conditional marketing authorisation
➡️ 1 had accelerated assessment
➡️ 2 were part of the #PRIME scheme

#EMAPresser

🐦🔗: https://nitter.cz/EMA_News/status/1747253499493261624#m

[2024-01-16 13:44 UTC]

R to @EMA_News: #Cancer is an area where top innovation and scientific progress happen quickly. That’s why EMA decided to use this therapeutic area as a pathfinder to improve medicines evaluation overall. #EMAPresser

🐦🔗: https://nitter.cz/EMA_News/status/1747253899109822673#m

[2024-01-16 13:46 UTC]

RT by @EMA_News: Evolution of #COVID19 variants remain a significant threat.

A joint procurement procedure for mRNA vaccines has been launched to enhance the #preparedness of participating countries.

Signature of a contract is foreseen in Spring, with no obligation to purchase.

#HealthUnion

🐦🔗: https://nitter.cz/EC_HERA/status/1747185167830012110#m

[2024-01-16 09:12 UTC]

At its Jan meeting, our safety committee the
https://nitter.cz/search?q=%23PRAC
:
✅recommended measures to address a potential risk of neurodevelopmental disorders in children born to men treated with
https://nitter.cz/search?q=%23valproate
✅started a review of
https://nitter.cz/search?q=%23CARTcell
💊
https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-january-2024

🐦🔗: https://nitter.cz/EMA_News/status/1745777485797622139#m

[2024-01-12 11:59 UTC]

Don't miss the EMA/
https://nitter.cz/EORTC
workshop exploring how patient reports on their own health and quality of life can inform regulatory decisions on
https://nitter.cz/search?q=%23cancertreatments
-
https://europa.eu/!TVfryM
📅 29 Feb
✍15 Jan deadline for in-person registration
💻 Online registration open until 16 Feb

🐦🔗: https://nitter.cz/EMA_News/status/1745702150221537525#m

[2024-01-12 07:00 UTC]

https://nitter.cz/search?q=%23UnitedInProtection
<p>
https://nitter.cz/EU_Health/status/1742120799249592510#m
</p>

🐦🔗: https://nitter.cz/EMA_News/status/1745473702328676487#m

[2024-01-11 15:52 UTC]